[144] Klaviyo, Inc. SEC Filing

Rhea-AI Filing Summary

Nutex Health Inc. (NASDAQ: NUTX) filed an 8-K reporting the imminent departure of Chief Operating Officer Joshua DeTillio. Mr. DeTillio notified the company on July 8, 2025 that he will resign effective August 8, 2025 to accept a chief executive role elsewhere. The filing states that his resignation is not related to any disagreement with Nutex Health’s operations, policies, or practices. The Board of Directors has begun a comprehensive search for a successor. No other management or financial information was disclosed in this report.

Positive

• None.

Negative

• COO resignation creates a leadership gap that could hinder operational execution until a qualified successor is onboarded.

Insights

Healthcare Sector Analyst

TL;DR: Key operating executive exits; limited immediate financial impact but raises execution risk.

COO departures can disrupt day-to-day operations, particularly for a multi-facility healthcare provider still scaling its platform. While the company states there is no disagreement and has launched a search, investors will watch closely for delays in strategic initiatives and additional turnover signals. The absence of financial or operational guidance update suggests no direct hit to 2025 outlook, yet succession clarity will be critical for confidence.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	60000	1950000.00	94683729	07/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2025	Restricted Stock Units	Issuer			60000	05/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for AMANDA WHALEN 125 Summer Street, 6th Floor Boston MA 02110	Common	06/13/2025	15000	502036.50
10b5-1 Sales for AMANDA WHALEN 125 Summer Street, 6th Floor Boston MA 02110	Common	05/16/2025	15000	524700.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

When is Nutex Health’s COO Joshua DeTillio leaving?

August 8, 2025 is the effective date of his resignation.

Why is the Nutex Health COO resigning?

He is departing to assume a chief executive officer position at another company; no disputes with NUTX were cited.

Did the filing cite any disagreements between Mr. DeTillio and Nutex Health?

No. The 8-K explicitly states there were no disputes or disagreements regarding company operations or policies.

What actions is Nutex Health taking to replace the COO?

The Board has initiated a comprehensive search for potential candidates to fill the COO role.

Does the 8-K include any updated financial guidance or results?

No. The filing is limited to the executive departure and contains no financial data or guidance updates.